Medtronic Inc. received U.S. regulatory approval to sell its minimally invasive heart valve technology, called CoreValve, for patients too frail for traditional surgery, the medical device maker said on Friday.. The U.S. Food and Drug Administration granted approval for CoreValve, used to replace damaged aortic valves, three months earlier than Medtronic had previously forecast. The approval allows the Minneapolis-based company to begin competing against rival Edwards Lifesciences Corp., whose similar device, called the Sapien,...
  